0001140361-14-046335.txt : 20141223
0001140361-14-046335.hdr.sgml : 20141223
20141223171041
ACCESSION NUMBER: 0001140361-14-046335
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141219
FILED AS OF DATE: 20141223
DATE AS OF CHANGE: 20141223
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001302573
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383572512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-995-8200
MAIL ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pollard-Knight Denise
CENTRAL INDEX KEY: 0001297000
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35993
FILM NUMBER: 141307651
MAIL ADDRESS:
STREET 1: C/O IDENIX PHARMACEUTICALS, INC.
STREET 2: 60 HAMPSHIRE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc1.xml
FORM 4
X0306
4
2014-12-19
0
0001302573
OncoMed Pharmaceuticals Inc
OMED
0001297000
Pollard-Knight Denise
C/O ONCOMED PHARMACEUTICALS, INC.
800 CHESAPEAKE DRIVE
REDWOOD CITY
CA
94063
1
0
0
0
Common Stock
2014-12-19
4
S
0
20654
21.7057
D
1964915
I
See Footnote
This transaction was executed in multiple trades in prices ranging from $21.60 to $21.87, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares of common stock of OMED are owned by Phase4 Ventures III LP ("Phase4"). The Reporting Person is a partner of Phase4 Partners Limited, which is the manager of Phase4. The Reporting Person disclaims beneficial ownership of the reported securities held by Phase4 except to the extent of her pecuniary interest therein.
/s/ Alicia J. Hager, Attorney-in-Fact for Denise Pollard-Knight
2014-12-23